Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13431734 | 1.00 | SRC (0.50) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL2174670 | 1.00 | SRC (0.50) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL12134271 | 0.82 | SRC (0.50) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL11462913 | 0.82 | SRC (0.50) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL8400939 | 0.81 | SRC (0.54) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL974061 | 0.79 | SRC (0.52) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL11404609 | 0.79 | SRC (0.52) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL14686240 | 0.77 | CYP2D6 (0.50) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL103235 | 0.77 | ALDH1A1 (0.54) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL155984 | 0.77 | ALDH1A1 (0.54) | SRCCYP2D6LMNAMAPK1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110172021-B | Separation and extraction method of (R) -o-chloromandelic acid | 武汉武药制药有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3875594-A1 | PREPARATION METHOD FOR (R)-O-CHLOROMANDELIC ACID AND CYCLIC BIOENZYME CATALYTIC REACTION SYSTEM FOR THE PREPARATION METHOD | Wuhan Wuyao Pharmaceutical Co., Ltd. (CN) | 2021-09-08 | — | — | EP | disclosed |
| CN-110172021-A | A kind of separating and extracting process of (R)-o-chloromandelic acid | 武汉武药制药有限公司 | 2019-08-27 | — | — | CN | disclosed |
| WO-2016021192-A1 | PROCESS FOR PRODUCTION OF (S)-(TETRAHYDROFURAN-3-YL)HYDRAZINE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-02-11 | — | — | WO | disclosed |
| US-20140350301-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | ACTAVIS GROUP PTC EHF (IS) | 2014-11-27 | — | — | US | disclosed |
| US-20140323727-A1 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2014-10-30 | — | — | US | disclosed |
| US-20130317220-A1 | NOVEL PROCESSES FOR PREPARING TRIAZOLO[4, 5-d]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-11-28 | — | — | US | disclosed |
| EP-2655341-A2 | NOVEL PROCESSES FOR PREPARING TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF | Actavis Group Ptc Ehf (IS) | 2013-10-30 | — | — | EP | disclosed |
| US-20130165696-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | ACTAVIS GROUP PTC EHF (IS) | 2013-06-27 | — | — | US | disclosed |
| US-20130150577-A1 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2013-06-13 | — | — | US | disclosed |
| EP-2588441-A2 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | Actavis Group Ptc Ehf (IS) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012085665-A2 | NOVEL PROCESSES FOR PREPARING TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF | ACTAVIS GROUP PATC EHF (IS) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012001531-A2 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | ACTAVIS GROUP PTC EHF (IS) | 2012-01-05 | — | — | WO | disclosed |
| JP-2002114737-A | METHOD FOR PRODUCING OPTICALLY ACTIVE o-CHLOROMANDELIC ACID | JAPAN HYDRAZINE CO INC | 2002-04-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317220-A1 | NOVEL PROCESSES FOR PREPARING TRIAZOLO[4, 5-d]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF | TBXAS1, TBXA2R, THPO | SRC 891/4885CYP2D6 66/4885LMNA 4759/4885 |
| US-20140350301-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | THPO, P2RY4, TBXA2R | SRC 1231/4885CYP2D6 96/4885LMNA 3776/4885 |
| US-20140323727-A1 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | THPO, P2RY4, TPMT | SRC 1685/4885CYP2D6 180/4885LMNA 3673/4885 |
| US-20130150577-A1 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | THPO, P2RY4, TPMT | SRC 1685/4885CYP2D6 180/4885LMNA 3673/4885 |
| US-20130165696-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | THPO, P2RY4, TBXA2R | SRC 1231/4885CYP2D6 96/4885LMNA 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.